Cytek Biosciences, Inc.
CTKB
$3.64
$0.041.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.46M | 57.48M | 51.50M | 46.62M | 44.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.46M | 57.48M | 51.50M | 46.62M | 44.86M |
| Cost of Revenue | 21.30M | 23.82M | 22.50M | 21.18M | 21.85M |
| Gross Profit | 20.16M | 33.65M | 29.01M | 25.44M | 23.01M |
| SG&A Expenses | 25.41M | 23.54M | 23.37M | 23.96M | 23.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.43M | 57.09M | 55.75M | 55.14M | 55.59M |
| Operating Income | -14.98M | 386.00K | -4.25M | -8.53M | -10.73M |
| Income Before Tax | -11.27M | 10.32M | 157.00K | -7.19M | -8.99M |
| Income Tax Expenses | 136.00K | 680.00K | -784.00K | 3.25M | -2.82M |
| Earnings from Continuing Operations | -11.40M | 9.64M | 941.00K | -10.43M | -6.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.40M | 9.64M | 941.00K | -10.43M | -6.17M |
| EBIT | -14.98M | 386.00K | -4.25M | -8.53M | -10.73M |
| EBITDA | -13.10M | 2.24M | -2.40M | -6.72M | -9.04M |
| EPS Basic | -0.09 | 0.07 | 0.01 | -0.08 | -0.05 |
| Normalized Basic EPS | -0.05 | 0.04 | 0.00 | -0.03 | -0.04 |
| EPS Diluted | -0.09 | 0.07 | 0.01 | -0.08 | -0.05 |
| Normalized Diluted EPS | -0.05 | 0.04 | 0.00 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 128.34M | 129.08M | 131.00M | 131.44M | 130.92M |
| Average Diluted Shares Outstanding | 128.34M | 129.08M | 132.79M | 131.44M | 130.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |